AgingResearch.NewsJoin free

BT-EXO-PT-miR-196 inhibitor

BT-EXO-PT-miR-196 inhibitor has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Oct 25, 2026: “Targeted RNA delivery alleviates bone loss in mice”.

Intervention

1 paper studies it1 findingUpdated

1 new paper in 30 daysSee all 1

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Animals1

What did studies of BT-EXO-PT-miR-196 inhibitor find?

1

Studies of BT-EXO-PT-miR-196 inhibitor measured 1 outcome; the most studied are bone loss (1 study).

Bone loss

downin mice1

1 study

  1. BT-EXO-PT-miR-196 inhibitor decreases bone loss in mice.

    “bone-targeted delivery of BT-Exo-Pt-miR-196 inhibitor effectively preserved trabecular bone microarchitecture, enhanced osteogenic activity, reduced osteoclast function, and alleviated bone loss”

    Animalsin an ovariectomy-induced osteoporosis mouse model

    Targeted RNA delivery alleviates bone loss in mice

    Materials today. Bio

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 11 paper in 12 months
Materials Today Bio

Targeted RNA delivery alleviates bone loss in mice

In a mouse model of osteoporosis caused by ovary removal, bone-targeted engineered vesicles preserved bone structure and reduced bone-breakdown activity without causing…In a mouse model of osteoporosis caused by ovary removal, bone-targeted engineered vesicles preserved bone structure and reduced bone-breakdown activity without causing systemic toxicity.

Mouse studyBones and joints
Paper

Related